Published in Leukemia on February 14, 2008
Translating p53 into the clinic. Nat Rev Clin Oncol (2010) 2.55
The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle (2009) 2.00
Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood (2013) 1.52
p53 Family and Cellular Stress Responses in Cancer. Front Oncol (2014) 1.33
Targeting p53 for Novel Anticancer Therapy. Transl Oncol (2010) 1.26
Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol (2013) 1.23
Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res (2013) 1.23
The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther (2010) 1.11
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One (2009) 1.01
Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways. Cancer Biol Ther (2010) 0.98
Novel therapies for aggressive B-cell lymphoma. Adv Hematol (2012) 0.94
Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos (2010) 0.94
Mdm2 links genotoxic stress and metabolism to p53. Protein Cell (2011) 0.92
Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia (2013) 0.91
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget (2015) 0.91
Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol Carcinog (2011) 0.88
Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Pharm Biomed Anal (2009) 0.86
Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One (2012) 0.86
Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des (2013) 0.84
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer (2011) 0.84
Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene (2011) 0.84
Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2. Neoplasia (2011) 0.84
Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2. PLoS One (2013) 0.83
Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Clin Cancer Res (2015) 0.82
Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma (2010) 0.82
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia (2011) 0.82
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients. Oncotarget (2016) 0.81
HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol (2012) 0.81
Pharmacological activation of wild-type p53 in the therapy of leukemia. Exp Hematol (2016) 0.79
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clin Cancer Res (2015) 0.79
Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer. Oncotarget (2016) 0.77
Chemical Variations on the p53 Reactivation Theme. Pharmaceuticals (Basel) (2016) 0.77
Context Sensitive Modeling of Cancer Drug Sensitivity. PLoS One (2015) 0.77
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer (2014) 0.76
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leuk Res (2016) 0.75
P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Front Pharmacol (2016) 0.75
Nutlin-3a selects for cells harbouring TP53 mutations. Int J Cancer (2016) 0.75
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem (2001) 4.21
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A (1985) 3.15
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene (2002) 3.12
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood (2005) 2.88
The human MDM-2 oncogene is overexpressed in leukemias. Blood (1993) 2.24
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood (2006) 1.71
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood (2005) 1.69
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood (2006) 1.49
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res (2006) 1.40
PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res (2003) 1.29
In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood (1997) 1.28
DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther (2002) 1.26
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood (1997) 1.18
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res (2007) 1.18
Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression. J Biol Chem (2003) 1.15
Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem (2002) 1.15
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood (1995) 1.07
Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia (2000) 1.06
Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells. Prostate (2007) 1.04
High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood (1996) 1.02
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene (2005) 1.01
Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood (1994) 1.00
Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. Oncogene (2006) 0.89
Mutations of the p53 gene in lymphoid leukemia. Blood (1991) 0.86
Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia (1992) 0.86
MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr Hematol Oncol (2001) 0.84
p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res (1999) 0.84
Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol (2000) 0.84
Inactivation of the p53 gene expression by a splice donor site mutation in a human T-cell leukemia cell line. Leukemia (1991) 0.83
Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol (1997) 0.83
Regulation of class II beta-tubulin expression by tumor suppressor p53 protein in mouse melanoma cells in response to Vinca alkaloid. Mol Cancer Res (2006) 0.82
Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Pediatr Hematol Oncol (1999) 0.82
In vitro drug sensitivity and apoptosis induction in newly diagnosed pediatric acute lymphoblastic leukemia: correlation with overall survival. Pediatr Hematol Oncol (2004) 0.78
High risk lymphoblastic leukemia in children: prognostic factors and management. Blood Rev (1987) 0.76
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 9.80
The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med (1994) 5.46
Segmented assimilation: issues, controversies, and recent research on the new second generation. Int Migr Rev (1997) 4.67
Mapping the conformational wave of acetylcholine receptor channel gating. Nature (2000) 4.00
The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J (1993) 3.80
Sodium channel mutations in paramyotonia congenita uncouple inactivation from activation. Neuron (1994) 3.67
A re-examination of adult mouse nicotinic acetylcholine receptor channel activation kinetics. J Physiol (1999) 2.49
Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. Proc Natl Acad Sci U S A (1994) 2.45
Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiol Genomics (2006) 2.38
Structure of the cytoplasmic beta subunit-T1 assembly of voltage-dependent K+ channels. Science (2000) 2.29
Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J (1997) 2.16
Sequence variation in the 18S rRNA gene, a target for PCR-based malaria diagnosis, in Plasmodium ovale from southern Vietnam. J Clin Microbiol (1996) 2.12
Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. Proc Natl Acad Sci U S A (1995) 2.08
Human HSP27 is phosphorylated at serines 78 and 82 by heat shock and mitogen-activated kinases that recognize the same amino acid motif as S6 kinase II. J Biol Chem (1992) 2.08
Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat Neurosci (1999) 1.93
Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor. Mol Cell Biol (1993) 1.91
Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry (2003) 1.89
The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J Biol Chem (1997) 1.87
Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene (2009) 1.85
Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol (1997) 1.84
Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther (2015) 1.81
An aspartic acid residue important for voltage-dependent gating of human muscle chloride channels. Neuron (1995) 1.79
SH2 domains exhibit high-affinity binding to tyrosine-phosphorylated peptides yet also exhibit rapid dissociation and exchange. Mol Cell Biol (1993) 1.77
Perioperative inflammatory response and protein S-100β concentrations - relationship with post-operative cognitive dysfunction in elderly patients. Acta Anaesthesiol Scand (2012) 1.69
Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol (2001) 1.67
MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells. Oncogene (2011) 1.59
The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol (2004) 1.59
Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells. Proc Natl Acad Sci U S A (1993) 1.58
Wide distribution of Plasmodium ovale in Myanmar. Trop Med Int Health (2002) 1.57
Quenched BODIPY dye-labeled casein substrates for the assay of protease activity by direct fluorescence measurement. Anal Biochem (1997) 1.55
K(+)-aggravated myotonia: destabilization of the inactivated state of the human muscle Na+ channel by the V1589M mutation. J Physiol (1994) 1.54
Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. Blood (1982) 1.52
Homotypic interaction and multimerization of hepatitis C virus core protein. Virology (1996) 1.51
Tumor necrosis factor-alpha produces hepatocellular dysfunction despite normal cardiac output and hepatic microcirculation. Am J Physiol (1993) 1.50
Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J Clin Invest (1999) 1.49
Functional expression of a rapidly inactivating neuronal calcium channel. Nature (1993) 1.48
Fluorometric method for the enzymatic determination of cholesterol. J Biochem Biophys Methods (1999) 1.47
A mutational analysis of the acetylcholine receptor channel transmitter binding site. Biophys J (1999) 1.42
Respiratory cancers and pollution. Eur Rev Med Pharmacol Sci (2015) 1.41
Dicationic diarylfurans as anti-Pneumocystis carinii agents. J Med Chem (1995) 1.38
The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil. Clin Pharmacol Ther (2011) 1.38
Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev (2006) 1.38
Community-based health insurance in China: bending to the wind of change. World Health Forum (1996) 1.38
RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol (2000) 1.36
An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A (2003) 1.33
A novel MaxiK splice variant exhibits dominant-negative properties for surface expression. J Biol Chem (2001) 1.33
Case-control study of risk factors for human infection with influenza A(H7N9) virus in Jiangsu Province, China, 2013. Euro Surveill (2013) 1.32
Probing the cathepsin D using a BODIPY FL-pepstatin A: applications in fluorescence polarization and microscopy. J Biochem Biophys Methods (2000) 1.31
Nonlinear theory for relativistic plasma wakefields in the blowout regime. Phys Rev Lett (2006) 1.30
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene (2011) 1.30
Remodeling of Kv4.3 potassium channel gene expression under the control of sex hormones. J Biol Chem (2001) 1.30
Evidence that complex formation by Bas1p and Bas2p (Pho2p) unmasks the activation function of Bas1p in an adenine-repressible step of ADE gene transcription. Mol Cell Biol (1997) 1.28
The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure (1997) 1.25
Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev (1999) 1.25
Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. Euro Surveill (2013) 1.24
Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience (2008) 1.24
The role of adrenomedullin in producing differential hemodynamic responses during sepsis. J Surg Res (2001) 1.23
Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci U S A (1998) 1.22
Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood (2001) 1.21
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood (1997) 1.21
Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice. Proc Natl Acad Sci U S A (2001) 1.19
NANOG modulates stemness in human colorectal cancer. Oncogene (2012) 1.19
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem (2001) 1.18
Stable patterns of allelic diversity at the Merozoite surface protein-1 locus of Plasmodium falciparum in clinical isolates from southern Vietnam. J Eukaryot Microbiol (1998) 1.16
Lipid peroxides induce expression of catalase in cultured vascular cells. J Lipid Res (2000) 1.16
Crystal structure of bovine low molecular weight phosphotyrosyl phosphatase complexed with the transition state analog vanadate. Biochemistry (1997) 1.15
Recombinant nucleocapsid protein is potentially an inexpensive, effective serodiagnostic reagent for infectious bronchitis virus. J Virol Methods (1998) 1.15
Genome-enabled hitchhiking mapping identifies QTLs for stress resistance in natural Drosophila. Heredity (Edinb) (2007) 1.15
Ageing alters the myosin heavy chain composition of single fibres from human skeletal muscle. Acta Physiol Scand (1990) 1.14
Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem (1997) 1.14
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma. Br J Cancer (2005) 1.12
Hormonal control of protein expression and mRNA levels of the MaxiK channel alpha subunit in myometrium. FEBS Lett (1999) 1.11
Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence. Proc Natl Acad Sci U S A (1998) 1.11
Dual role of fibronectin in hematopoietic differentiation. Blood (1989) 1.11
Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues. Biochemistry (1998) 1.10
Chromophore attachment to biliproteins: specificity of PecE/PecF, a lyase-isomerase for the photoactive 3(1)-cys-alpha 84-phycoviolobilin chromophore of phycoerythrocyanin. Biochemistry (2001) 1.10
Gut-derived norepinephrine plays a critical role in producing hepatocellular dysfunction during early sepsis. Am J Physiol Gastrointest Liver Physiol (2000) 1.10
Release of the neuregulin functional polypeptide requires its cytoplasmic tail. J Biol Chem (1998) 1.07
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood (1995) 1.07
Up-regulation of a novel potent vasodilatory peptide adrenomedullin during polymicrobial sepsis. Shock (1998) 1.06
Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia (2000) 1.06
Cloning and sequence analysis of a protective M-like protein gene from Streptococcus equi subsp. zooepidemicus. Infect Immun (1995) 1.05
Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J Agric Food Chem (2000) 1.05
Role of gap3 in Fap1 glycosylation, stability, in vitro adhesion, and fimbrial and biofilm formation of Streptococcus parasanguinis. Oral Microbiol Immunol (2008) 1.04
Independent binding of peptide ligands to the SH2 and SH3 domains of Grb2. J Biol Chem (1994) 1.03
Intracrine and autocrine effects of basic fibroblast growth factor in vascular smooth muscle cells. J Mol Cell Cardiol (1997) 1.02
Norepinephrine-induced hepatocellular dysfunction in early sepsis is mediated by activation of alpha2-adrenoceptors. Am J Physiol Gastrointest Liver Physiol (2001) 1.02
Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo. Int Immunol (1996) 1.00
Resting murine neutrophils express functional alpha 4 integrins that signal through Src family kinases. J Immunol (2001) 1.00
In vivo imaging of rat cortical bone porosity by synchrotron phase contrast micro computed tomography. Phys Med Biol (2014) 1.00
Improving return rates for health-care outcome. Psychol Rep (2000) 0.99
Alternative splicing and hypermutation of a nonproductively rearranged TCR alpha-chain in a T cell hybridoma. J Immunol (1999) 0.99
Magnet used for protein crystallization: novel attempts to improve the crystal quality. Biochem Biophys Res Commun (2000) 0.99
The tax protein from the primate T-cell lymphotropic virus type 3 is expressed in vivo and is functionally related to HTLV-1 Tax rather than HTLV-2 Tax. Oncogene (2006) 0.99
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab (2009) 0.98
Congenital fistula of the palate. J Craniomaxillofac Surg (1998) 0.98
In vitro selection of sequence contexts which enhance bypass of abasic sites and tetrahydrofuran by T4 DNA polymerase holoenzyme. J Mol Biol (1999) 0.97
A novel putative protein-tyrosine phosphatase contains a BRO1-like domain and suppresses Ha-ras-mediated transformation. J Biol Chem (1998) 0.97